Araclon Biotech is a newly founded company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, in particular, to date, to Alzheimer’s disease. Currently, Araclon is working on three different projects,
The first one focuses on the diagnosis of Alzheimer’s disease （with a patented detection kit for Beta-amyloid 40 and 42 proteins in blood）.
The second one on immunotherapy.
And the last one is an emerging project which tries to answer the challenge of predicting Alzheimer’s disease in totally asymptomatic individuals.